Misonix Inc. announced the appointment of Scott Ludecker as Vice President of Global Sales and Marketing. Mr. Ludecker will oversee all sales and marketing activities for Misonix worldwide. With more than 20 years of experience in the global medical device industry, Scott Ludecker has a demonstrated track record of successfully commercializing medical technology and in building and managing global sales distribution networks. Mr. Ludecker most recently served as Vice President of Global Sales and Marketing for BioMimetic Therapeutics. He was responsible for building the commercial launch strategy and the associated infrastructure to support a global product launch for BioMimetic's regenerative medicine platform technology.

Misonix Inc. announced that Mr. Stavros Vizirgianakis has been appointed to the company board of directors. The addition of Mr. Vizirgianakis expands the company Board to seven members, with five members considered to be independent directors. Mr. Vizirgianakis is a company shareholder, having acquired 5.3% of the company's outstanding common stock in the open market in recent years. Stavros Vizirgianakis has extensive medical device sales and marketing experience as a principal in Applied BioSurgical, a large medical device distributor in South Africa, and as a partner in MD Solutions Australasia PTY LTD. Both companies are major distributors for a large number of medical device companies throughout the world.

Misonix Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. For the quarter, the company reported net sales of $3,023,487, comparable to $3,609,746 in the third quarter of 2012. Loss from operations was $1,759,074 against $484,598 a year ago. Loss from continuing operations before income taxes was $759,463 against $362,276 a year ago. Net loss from continuing operations was $700,337 or $0.10 per diluted share against $276,414 or $0.04 per diluted share a year ago. Net loss was $528,330 or $0.08 per diluted share against $214,625 or $0.03 per diluted share a year ago. For the nine months, the company’s net sales for the nine months increased 7% to $11,068,243 compared to $10,377,480 in the first nine months of 2012. Loss from operations was $3,087,777 against $1,690,010 a year ago. Loss from continuing operations before income taxes was $1,374,362 against $1,140,589 a year ago. Net loss from continuing operations was $1,319,065 or $0.19 per diluted share against $852,454 or $0.12 per diluted share a year ago. Net loss was $1,137,265 or $0.16 per diluted share against $78,488 or $0.01 per diluted share a year ago. The company's provided $131,000 of cash flow from operating activity compared with $1.6 million of cash used in operating activities for the nine months ended March 31, 2012.